%0 Consensus Development Conference
%T Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference.
%A Baiocchi GL
%A D'Ugo D
%A Coit D
%A Hardwick R
%A Kassab P
%A Nashimoto A
%A Marrelli D
%A Allum W
%A Berruti A
%A Chandramohan SM
%A Coburn N
%A Gonzàlez-Moreno S
%A Hoelscher A
%A Jansen E
%A Leja M
%A Mariette C
%A Meyer HJ
%A Mönig S
%A Morgagni P
%A Ott K
%A Preston S
%A Rha SY
%A Roviello F
%A Sano T
%A Sasako M
%A Shimada H
%A Schuhmacher C
%A So Bok-Yan J
%A Strong V
%A Yoshikawa T
%A Terashima M
%A Ter-Ovanesov M
%A Van der Velde C
%A Memo M
%A Castelli F
%A Pecorelli S
%A Detogni C
%A Kodera Y
%A de Manzoni G
%J Gastric Cancer
%V 19
%N 1
%D Jan 2016
%M 26140915
%F 7.701
%R 10.1007/s10120-015-0513-0
%X <B>OBJECTIVE: </B>Presently, there is no scientific evidence supporting a definite role for follow-up after gastrectomy for cancer, and clinical practices are quite different around the globe. The aim of this consensus conference was to present an ideal prototype of follow-up after gastrectomy for cancer, based on shared experiences and taking into account the need to rationalize the diagnostic course without losing the possibility of detecting local recurrence at a potentially curable stage.<BR><B>METHODS: </B>On June 19-22, 2013 in Verona (Italy), during the 10th International Gastric Cancer Congress (IGCC) of the International Gastric Cancer Association, a consensus meeting was held, concluding a 6-month, Web-based, consensus conference entitled "Rationale of oncological follow-up after gastrectomy for cancer."<BR><B>RESULTS: </B>Forty-eight experts, with a geographical distribution reflecting different health cultures worldwide, participated in the consensus conference, and 39 attended the consensus meeting. Six statements were finally approved, displayed in a plenary session and signed by the vast majority of the 10th IGCC participants. These statements are attached as an annex to the Charter Scaligero on Gastric Cancer.<BR><B>CONCLUSIONS: </B>After gastrectomy for cancer, oncological follow-up should be offered to patients; it should be tailored to the stage of the disease, mainly based on cross-sectional imaging, and should be discontinued after 5 years.